Karl L. Insogna, MD

Professor of Medicine (Endocrinology); Director, Yale Bone Center

Clinical Interests

  • Hyperthyroidism
  • Medical Oncology
  • Osteoporosis

Patient Care

Accepts new patients? No
Patient Type: Adult
Referrals: From physicians only

Patient Care Organizations

Cancer Center, Yale

Center for X-Linked Hypophosphatemia, Yale

Internal Medicine: Diabetes Research Center | Endocrinology: Bone Center

Yale Medical Group

Clinical Trials

Conditions Study Title
A Phase 2 open-label trial to assess the efficacy and safety of KRN23, an antibody to FGF23, in patients with tumor-induced osteomalacia (TIO) or epidermal nevus syndrome (ENS)
A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects with X-Linked Hypophosphatemia (XLH)
A Randomized Open-Label, Dose Evaluation, Parallel Group Phase 2 Study to Assess the Pharmacodynamics and Safety of the anti-FGF23 antibody, KRN23, in Pediatric Patients with X-linked Hypophosphatemia (XLH)
X-linked Hypophosphatemic Rickets International Registry
Identification of Phosphate Transport Inhibitory Activity in Tissues or Tumors from Subjects with Renal Phosphate Wasting
A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents and Young Adults Treated with Glucocorticoids
Calcitonin to lower FGF23 levels in patients with X-linked hypophosphatemia
A Study to Evaluate Disorders of Calcium Metabolism
The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets

Edit this profile